![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, August 18, 2015 1:55:14 PM
I will glady agree that they need a facility to product their materials and the plan they announced years ago was that they preferred to build their own instead of hiring an existing facility due to the need to retrofit an existing facility and train a staff on processes that may be proprietary.
What they failed to disclose then was that even with a new facility, they had no way to produce the materials at levels necessary to complete Tox, let alone, for commercialization.
Now will you "own up" to the fact that MERS with PHE is not currently active (and likely never will be)? And that Ebola was a waste of time and materials (and may have been a big factor in the recent demise of the SP (making their fast development in field claims suspect)? And that they have yet to scale to 500g? And that Tox is currentl at a complete stand still? And that good old Dr. Harris has all but disappeared along with any movement on Dengue? And that saying they are now done with scale-up studies is a completely irrelevant and meaningless statement given that they can not currently produce at levels necessary to complete Tox and have stated that they have 25 new scientists and technicians working on trying to figure out scale up?
Shall I go on?
The lab was designed to be a means of wealth diversification for Diwan. He washed the shares and got cash all under the guise of "helping the company".
He will get the facility in the BK. Nice return on his investment. Fully reimbursed for expenses, plus getting the facility.
I keep telling you, these guys are good! (just not good at what investors need them to be good at)
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM